Physician

Tejvir Singh, M.D.

According to 2025 Medicare claims, Tejvir Singh, M.D. (NPI: 1932139136) practices internal medicine in the Reno, NV market, with the plurality of this provider's patient population coming from Washoe, NV. This provider's primary affiliated billing organization is JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFESSIONAL CORPORATION (NPI: 1861514580; TIN: 880152239) and primary practice location at 89511-2250. Singh is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 804 traditional Medicare patients, billed 187,703 HCPCS/CPT codes, and received $3,896,867 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,990 prescription claims across 284 beneficiaries totaling $7,251,720 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 50 claims. Open Payments data shows 64 records totaling $7,086. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,980,103 to $3,896,867. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,221,059 to $7,251,720. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,689 to $378.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	490	102,958	$1,980,103
2016	518	115,775	$2,333,563
2017	601	118,488	$2,384,339
2018	649	143,795	$2,840,252
2019	724	149,440	$3,097,796
2020	778	164,510	$3,728,968
2021	801	188,564	$3,787,733
2022	701	148,431	$3,040,846
2023	789	215,558	$4,443,548
2024	804	187,703	$3,896,867

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	196	1,437	$1,221,059
2016	215	1,455	$1,556,914
2017	205	1,320	$1,813,098
2018	212	1,168	$2,062,434
2019	251	1,278	$3,009,551
2020	245	1,378	$2,632,636
2021	258	1,514	$4,023,698
2022	258	1,475	$4,298,140
2023	270	1,597	$4,540,739
2024	284	1,990	$7,251,720

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	261	$105,420
2016	N/R	106	$17,308
2017	N/R	112	$12,133
2018	N/R	60	$8,244
2019	N/R	30	$1,869
2020	N/R	59	$5,249
2021	N/R	24	$1,377
2022	N/R	41	$2,226
2023	N/R	27	$14,218
2024	N/R	50	$1,588

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	186	388	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	536	1,409	$95
80053	Blood test, comprehensive group of blood chemicals	389	746	$10
36415	Insertion of needle into vein for collection of blood sample	494	1,284	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	513	1,417	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	40	1,120	$941,948
Imbruvica	Ibrutinib	34	952	$556,693
Keytruda	Pembrolizumab	46	980	$498,356
Revlimid	Lenalidomide	32	896	$488,431
Lenalidomide	Lenalidomide	28	784	$475,943

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$930
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$357
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	64	$7,086	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tejvir Singh, M.D.?

Tedicare shows public-source Medicare data for Tejvir Singh, M.D. (NPI 1932139136), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tejvir Singh, M.D. have ACO affiliation data?

Tejvir Singh, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Tejvir Singh, M.D.?

Tejvir Singh, M.D. is linked to JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFESSIONAL CORPORATION (billing NPI 1861514580) in the available physician profile data.

Does Tejvir Singh, M.D. have Open Payments data?

Tejvir Singh, M.D. has 64 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.